Pekka Simula joins Sartar’s board of directors

Sartar strengthens the board of directors. CEO of Herantis Pharma, Pekka Simula, has been appointed as a new member to the Sartar Therapeutics board of directors.

BioInvestor Forum and Global SPARK Showcase, San Franscisco, California, October 16-18, 2018

Sartar will pitch at BioInvestor Forum and Global SPARK Showcase events. Meet us there!

The Anglonordic Life Science Conference LONDON, May 24, 2018

Meet us at the Anglonordic Life Science Conference in London.

Charité BIH Entrepreneurship Summit Berlin, May 7 – 8, 2018

Sartar will pitch at the Life Sciences Venture Market 2018!

The 2nd KYOTO−SPARK Symposium February 14, 2018

Sartar will give a presentation at the 2nd KYOTO−SPARK Symposium.

Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation

The Vice-Chairman of the Board and a co-founder the Sartar Therapeutics Professor Heikki Joensuu has been appointed Vice President of Therapy area Oncology, R&D in Orion Corporation. Congratulations Heikki on your new appointment!

Sartar was awarded a U.S. patent 16.10.2017

Sartar was awarded a USA patent for use of anagrelide in cancer therapy.

Sartar won HealthBIO pitching competition 9.10.2017

Sartar Therapeutics participated to the HealthBIO pitching competition and won it.

BIO-Europe Berlin November 6–8, 2017

Sartar will participate in the Next Generation tract company presentations in the BIO-Europe conference at Wednesday 8th of November.

HealthBIO Seminar and Partnering Event in Turku 5-6.9.2017

Sartar participates in HealthBIO partnering event.

Sartar was chosen to SPARK Finland program starting at 2.5.2017

SPARK Finland program is designed to increase the maturity of academic and clinical discoveries towards practical solutions in the life science and health tech space.

Sartar starts at Life Science Accelerator program in Turku 27.3.2017

Life Science Accelerator is a national initiative to access the untapped innovation potential within university research and young companies and to create new successful business. The initiative is partly funded by ERDF funding.